Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirogabalin (Primary) ; Pregabalin
  • Indications Fibromyalgia; Pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 31 Aug 2017 According to a Daiichi Sankyo media release, the results from the global clinical development program consisting of several phase 3 clinical trials, including NEUCOURSE, REDUCER and ALDAY, will serve as the basis for potential regulatory submissions in various countries.
    • 30 Jun 2017 According to a Daiichi Sankyo media release, full results from this trial will be disclosed in upcoming scientific mediums.
    • 30 Jun 2017 Results from this trial published in a Daiichi Sankyo Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top